Kontro Lab

Novel treatments for acute myeloid leukemia #FIMM_UH

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring

Read more in depth 👉https://t.co/wmGENiPd1K

[Kontro Lab @LabKontro]

Our latest @Hemasphere_EHA study from @FIMM_UH defines key signatures of #venetoclax + hypomethylating agent #resistance in #AML and highlights strategies for targeting resistant disease.

Read more: https://t.co/EflicDst4Y

[Fadi Haddad, MD @FadiHaddad_MD]

Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB)

@myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan

[Kontro Lab @LabKontro]

New findings from our VenEx trial in #AML: venetoclax resistance linked to altered apoptosis & PRAME overexpression. Exploring PRAME-targeted immunotherapy + apoptosis modulators. Grateful for Jane and Aatos Erkko Foundation support to advance this research. #JAES

[Basic & Clinical Pharmacology & Toxicology @BasClinPharmTox]

1/4

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial

New study by @LabKontro and colleagues – study highlights 👇

[Kontro Lab @LabKontro]

Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, @helsinkiuni and @FIMM_UH published now in @BloodJournal

[Blood Journals Portfolio @BloodPortfolio]

VenEx trial showed that ex vivo drug sensitivity is beneficial for selecting patients with R/R or sAML for venetoclax-azacitidine therapy. https://t.co/IQpKqiLw1p #clinicaltrialsandobservations #myeloidneoplasia

[FIMM HelsinkiUni @FIMM_UH]

Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy.
New @LabKontro results allow treatments to be tailored to those who are most likely to benefit.
📰@HUS_fi:
https://t.co/coAjWznMk1

[FIMM HelsinkiUni @FIMM_UH]

Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle.
@LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille.
📰@HUS_fi: https://t.co/tYJl9GWFfO

[Kontro Lab @LabKontro]

Dr. Mika Kontro from @KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN+AZA responses in AML.

[FCI Finnish Cancer Institute @CancerInstFIN]

Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇https://t.co/TbhJaJkNI9

[FIMM HelsinkiUni @FIMM_UH]

A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm.
https://t.co/xxIUL1s6wz

[Heikki Kuusanmäki @hkuusanm]

1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal

https://t.co/ktzWK6VxGT

[Kontro Lab @LabKontro]

Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible @Haematologica

https://t.co/qAhqtRMni3

[Olli Dufva @ollidufva]

Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients @LabKontro #ASH22

[Kontro Lab @LabKontro]

Excellent talk by @josephsaad95 on NAMPT inhibitors in AML with monosomy 7/del(7q) yesterday at #ASH22!

[Kontro Lab @LabKontro]

Ex vivo drug sensitivity testing predicts venetoclax+azacitidine treatment responses in AML. VenEx trial interim results presented at #ASH21